SCHEMBL12410751

SCHEMBL12410751

CC(C)(C)n1cnc2ncccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.35
BACE1 P56817 1/20 0.35
NPC1 O15118 7/20 0.35
RAB9A P51151 6/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 4/20 0.33
TP53 P04637 2/20 0.33
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
THRB P10828 1/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867385 0.81 LTA4H (0.35) LTA4HBACE1KMT2AALDH1A1L3MBTL1
SCHEMBL18188312 0.81 LTA4H (0.35) LTA4HBACE1KMT2A
SCHEMBL21475765 0.79 LTA4H (0.33) LTA4HBACE1
SCHEMBL21363616 0.77 IDO1 (0.40) KMT2AKDM4EMEN1LMNA
SCHEMBL4870504 0.76 MKNK1 (0.34) LTA4H
SCHEMBL4868166 0.74 IDO1 (0.37) HPGDALDH1A1KDM4EMAPTTP53
SCHEMBL30178291 0.74 LTA4H (0.41) LTA4HBACE1NPC1RAB9AKMT2A
SCHEMBL256361 0.74 LTA4H (0.41) LTA4HBACE1NPC1RAB9AKMT2A
SCHEMBL4865112 0.73 KDM4E (0.36) BACE1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL4865116 0.73 KDM4E (0.36) BACE1RAB9AKMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753381-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-09-12 US disclosed
US-20210379113-A1 METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY EDIGENE BIOTECHNOLOGY, INC. (CN) 2021-12-09 US disclosed
US-20200039989-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2020-02-06 US disclosed
US-20190343885-A1 COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY EDIGENE BIOTECHNOLOGY, INC. (CN) 2019-11-14 US disclosed
US-20190314407-A1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS EDIGENE BIOTECHNOLOGY, INC. (CN) 2019-10-17 US disclosed
US-10351572-B2 Aryl hydrocarbon receptor antagonists and uses thereof Magenta Therapeutics Inc. (US) 2019-07-16 US disclosed
US-20190177330-A1 ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF EDIGENE BIOTECHNOLOGY, INC. (CN) 2019-06-13 US disclosed
US-20180170942-A1 POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIO INC (US) 2018-06-21 US disclosed
US-20180170942-A1 POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS NANTBIO INC (US) 2018-06-21 US disclosed
US-9969724-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2018-05-15 US disclosed
US-9808445-B2 Factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2017-11-07 US disclosed
US-20170129880-A1 FACTOR IXa INHIBITORS MERCK SHARP & DOHME LLC 2017-05-11 US disclosed
US-20170027916-A1 FACTOR IXa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-02 US disclosed
US-20140309413-A1 METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-16 US disclosed
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2011-03-10 US disclosed
US-7767687-B2 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors BIOGEN IDEC MA INC. (US) 2010-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129880-A1 FACTOR IXa INHIBITORS F9, F12, TFPI LTA4H 932/4885BACE1 899/4885NPC1 2231/4885
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD LTA4H 2645/4885BACE1 3771/4885NPC1 372/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD LTA4H 2645/4885BACE1 3771/4885NPC1 372/4885
US-11753381-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 LTA4H 3706/4885BACE1 1463/4885NPC1 1506/4885
US-20180170942-A1 POLYCYCLIC DERIVATIVES TARGETING RAL GTPASES AND THEIR THERAPEUTICAL APPLICATIONS KRAS, HRAS, RALA LTA4H 3729/4885BACE1 4003/4885NPC1 1365/4885
US-20200039989-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK1, CLK3 LTA4H 1521/4885BACE1 2119/4885NPC1 3961/4885
US-20210379113-A1 METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY HCLS1, MPST, THPO LTA4H 1716/4885BACE1 4568/4885NPC1 61/4885
US-20170027916-A1 FACTOR IXa INHIBITORS F9, F12, TFPI LTA4H 932/4885BACE1 899/4885NPC1 2231/4885
US-20190343885-A1 COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANT THERAPY MCL1, HCLS1, KIT LTA4H 1295/4885BACE1 4784/4885NPC1 1271/4885
US-10351572-B2 Aryl hydrocarbon receptor antagonists and uses thereof AHR, ARNT, AIPL1 LTA4H 469/4885BACE1 4209/4885NPC1 2005/4885
US-20140309413-A1 METHODS OF STEREOSELECTIVE SYNTHESIS OF SUBSTITUTED NUCLEOSIDE ANALOGS NUDT1, PAPSS1, NT5C3B LTA4H 2117/4885BACE1 3899/4885NPC1 854/4885
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF LTA4H 3115/4885BACE1 3510/4885NPC1 4187/4885
US-20190314407-A1 COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AHR, HCLS1, IL2RA LTA4H 655/4885BACE1 4422/4885NPC1 1492/4885
US-20190177330-A1 ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF AHR, ARNT, AIPL1 LTA4H 469/4885BACE1 4209/4885NPC1 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.